135 related articles for article (PubMed ID: 2963208)
1. Binding of [125I]-N-(p-aminophenethyl)spiroperidol to the D-2 dopamine receptor in the neurointermediate lobe of the rat pituitary gland: a thermodynamic study.
Agui T; Amlaiky N; Caron MG; Kebabian JW
Mol Pharmacol; 1988 Feb; 33(2):163-9. PubMed ID: 2963208
[TBL] [Abstract][Full Text] [Related]
2. The thermodynamics of agonist and antagonist binding to dopamine D-2 receptors.
Kilpatrick GJ; el Tayar N; Van de Waterbeemd H; Jenner P; Testa B; Marsden CD
Mol Pharmacol; 1986 Sep; 30(3):226-34. PubMed ID: 2943980
[TBL] [Abstract][Full Text] [Related]
3. Chronic estrogen treatment promotes a functional uncoupling of the D2 dopamine receptor in rat anterior pituitary gland.
Munemura M; Agui T; Sibley DR
Endocrinology; 1989 Jan; 124(1):346-55. PubMed ID: 2521206
[TBL] [Abstract][Full Text] [Related]
4. Thermodynamic differences between agonist and antagonist interactions with binding sites for [3H]spiroperidol in rat striatum.
Zahniser NR; Molinoff PB
Mol Pharmacol; 1983 Mar; 23(2):303-9. PubMed ID: 6835199
[TBL] [Abstract][Full Text] [Related]
5. Interaction of [3H]spiperone with rat striatal dopamine D-2 receptors: kinetic evidence for antagonist-induced formation of ternary complex.
Chatterjee TK; Scott CE; Vazquez DM; Bhatnagar RK
Mol Pharmacol; 1988 Apr; 33(4):402-13. PubMed ID: 3357484
[TBL] [Abstract][Full Text] [Related]
6. Characterization of D-2 dopamine receptors in a tumor of the rat anterior pituitary gland.
Lin C; McGonigle P; Molinoff PB
J Pharmacol Exp Ther; 1987 Sep; 242(3):950-6. PubMed ID: 2958621
[TBL] [Abstract][Full Text] [Related]
7. [3H]spiroperidol identifies a D-2 dopamine receptor inhibiting adenylate cyclase activity in the intermediate lobe of the rat pituitary gland.
Frey EA; Cote TE; Grewe CW; Kebabian JW
Endocrinology; 1982 Jun; 110(6):1897-904. PubMed ID: 7075543
[TBL] [Abstract][Full Text] [Related]
8. Sodium-dependent isomerization of dopamine D-2 receptors characterized using [125I]epidepride, a high-affinity substituted benzamide ligand.
Neve KA; Henningsen RA; Kinzie JM; De Paulis T; Schmidt DE; Kessler RM; Janowsky A
J Pharmacol Exp Ther; 1990 Mar; 252(3):1108-16. PubMed ID: 2138666
[TBL] [Abstract][Full Text] [Related]
9. Dopamine D2 receptors in the anterior pituitary: a single population without reciprocal antagonist/agonist states.
George SR; Watanabe M; Seeman P
J Neurochem; 1985 Apr; 44(4):1168-77. PubMed ID: 2579204
[TBL] [Abstract][Full Text] [Related]
10. [3H]Ro 22-1319 (piquindone) binds to the D2 dopaminergic receptor subtype in a sodium-dependent manner.
Nakajima T; Iwata K
Mol Pharmacol; 1984 Nov; 26(3):430-8. PubMed ID: 6149457
[TBL] [Abstract][Full Text] [Related]
11. Characterization of [125I](R)-trans-7-hydroxy-2-[N-propyl-N-(3'-iodo-2'-propenyl)amino] tetralin binding to dopamine D3 receptors in rat olfactory tubercle.
Burris KD; Filtz TM; Chumpradit S; Kung MP; Foulon C; Hensler JG; Kung HF; Molinoff PB
J Pharmacol Exp Ther; 1994 Feb; 268(2):935-42. PubMed ID: 8114008
[TBL] [Abstract][Full Text] [Related]
12. Regulation of dopamine D2 receptors in a novel cell line (SUP1).
Ivins KJ; Luedtke RR; Artymyshyn RP; Molinoff PB
Mol Pharmacol; 1991 Apr; 39(4):531-9. PubMed ID: 1708089
[TBL] [Abstract][Full Text] [Related]
13. Evidence that the D-2 dopamine receptor in the intermediate lobe of the rat pituitary gland is associated with an inhibitory guanyl nucleotide component.
Cote TE; Frey EA; Grewe CW; Kebabian JW
J Neural Transm Suppl; 1983; 18():139-47. PubMed ID: 6308147
[TBL] [Abstract][Full Text] [Related]
14. Distinctions between ligand-binding sites for [3H]dopamine and D2 dopaminergic receptors characterized with [3H]spiroperidol.
Hancock AA; Marsh CL
Mol Pharmacol; 1984 Nov; 26(3):439-51. PubMed ID: 6238230
[TBL] [Abstract][Full Text] [Related]
15. Dopamine D1 receptors of the calf parathyroid gland: identification and characterization.
Niznik HB; Fogel EL; Chen CJ; Congo D; Brown EM; Seeman P
Mol Pharmacol; 1988 Jul; 34(1):29-36. PubMed ID: 2839763
[TBL] [Abstract][Full Text] [Related]
16. A photoaffinity ligand for dopamine D2 receptors: azidoclebopride.
Niznik HB; Guan JH; Neumeyer JL; Seeman P
Mol Pharmacol; 1985 Feb; 27(2):193-9. PubMed ID: 3969068
[TBL] [Abstract][Full Text] [Related]
17. Phenoxybenzamine treatment differentiates dopaminergic 3H-ligand binding sites in bovine caudate membranes.
Hamblin MW; Creese I
Mol Pharmacol; 1982 Jan; 21(1):44-51. PubMed ID: 6127621
[TBL] [Abstract][Full Text] [Related]
18. Characterization of membrane-bound and soluble D2 receptors in canine caudate using [125I]IBZM.
Schonwetter BS; Luedtke RR; Kung MP; Billings J; Kung HF; Molinoff PB
J Pharmacol Exp Ther; 1989 Jul; 250(1):110-6. PubMed ID: 2526213
[TBL] [Abstract][Full Text] [Related]
19. Regulation of dopamine D2 receptors by sodium and pH.
Neve KA
Mol Pharmacol; 1991 Apr; 39(4):570-8. PubMed ID: 2017157
[TBL] [Abstract][Full Text] [Related]
20. Interactions of dopaminergic agonists and antagonists with dopaminergic D3 binding sites in rat striatum. Evidence that [3H]dopamine can label a high affinity agonist-binding state of the D1 dopamine receptor.
Leff SE; Creese I
Mol Pharmacol; 1985 Feb; 27(2):184-92. PubMed ID: 3969067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
